Hypertension Busan 2020

in Conjunction with the 52nd Scientific Meeting of the
Korean Society of Hypertension

2020.8. 7 (Fri) - 8 (Sat) BEXCO, Busan, Korea

HOME  >  Speakers

Speakers

Abdul Rashid

Consultant Physician,
Visiting Professor and Medical Director / Malaysia

Session Joint Symposium of KSH/Malaysian Hypertension Society
[How to Manage Prehypertension Epidemics and Risk Factor Clustering]
Lecture Title National Governmental Policy to Enhance Hypertension Control in Malaysia
Lecture
Introduction
Hypertension remains a public health scourge globally and especially in developing countries. In the Asia Pacific Region, prevalence, awareness, treatment and control rates lag far behind that of Canada, USA and UK. In some parts of Asia concerted efforts are being made to address the short fall with varied results. In Malaysia efforts to understand the true burden of hypertension began in earnest 3 decades ago beginning with understanding the epidemiology, implementing public health education strategy, targeted screening program, drafting national treatment guidelines and continuous audits of performance. Results of this efforts will be discussed and shortcomings highlighted for future improvement.
Close

Eugene Yang

University of Washington School of Medicine / USA

Session Meet the Expert II: Keywords in the Patient Centeredness in Hypertension [Eng]
Lecture Title Team-based Approach to Blood Pressure Management- Review of 2017 ACC/AHA Hypertension Guidelines
Lecture
Introduction
Blood pressure control remains low in the United States despite efforts to increase education and awareness- With implementation of the 2017 ACCIAHA guidelines, BP control rates have now fallen below 50%. In this presentation, we will review the updated American BP guideline recommendations for team-based care deliver systems for hypertension management and highlight recent studies that demonstrate the efficacy of these approaches.
Close

Fumiaki Ikeno

Stanford University / USA

Session New Approach in Hypertension and Cardiovascular Diseases
Lecture Title The Trend of New Technology of Cardiovascular Field from Silicon Valley
Lecture
Introduction
TBD
Close

Gianfranco Parati

University of Milan-Bicocca / Italy

Session Plenary Lecture
Lecture Title Blood Pressure Variability: a Target for Treatment in Hypertension?
Lecture
Introduction
A large body of evidence suggests that the risk associated to hypertension may not only depend on the magnitude of average BP levels elevation, but also on the presence of an increased BP variability (BPV). Indeed, increased BPV either in the short term (24 hours), in the midterm (day-by-day), or in the long term (visit-to-visit), may predict development, progression, and severity of cardiac, vascular, and renal organ damage, as well as cardiovascular events and mortality. Whether BPV indices might represent useful parameters in clinical practice and whether an increased BPV should be a target for treatment, this is still a matter of discussion, however. This lecture will review the available data on mechanisms, methodological aspects, clinical relevance and therapeutic implications of BPV.
Close

Phillip C. Yang

Stanford University / USA

Session Update of Pulmonary Hypertension Imaging 2020
Lecture Title Multi-modality Imaging of Pulmonary Hypertension
Lecture
Introduction
Pressure in the arteries to and inside the lungs. The etiology is multifactorial. It could be due to intrinsic lung disorder such as COPD, emboli, inflammation, or idiopathic. Other etiologies include drugs, cardiovascular, congenital heart, rheumatologic, liver, and autoimmune diseases. Given the extensive physiologic impact, clinical symptoms and manifestation of this disorder are extensive. Imaging tools are critical in diagnosing, treating, and prognosticating this highly morbid affliction. This lecture will discuss the advanced, multi-modality imaging technology to advance the outcome in patients suffering from pulmonary hypertension. The clinical roles of echocardiography, MRI, and CT will be demonstrated, using novel imaging of pulmonary hypertension.
Close

Tim Anstiss

British Medical Association,
British Psychological Society / UK

Session Special Lecture
Lecture Title Getting Your Patient to Look after Their Health. a Quick Taste of Motivational Interviewing
Lecture
Introduction
In this lecture I will give a demonstration of two different styles of talking with people about making a behavior change, and we will discuss good conversational practice in activating and empowering patients to control their blood pressure and reduce their risk of complications.
Session Meet the Expert II: Keywords in the Patient Centeredness in Hypertension [Eng]
Lecture Title Conventional Education versus Coaching
Lecture
Introduction
Patients spend over 8,000 hours every year with their hypertension, compared to just a few hours each year with their doctor. If we want our patients to better manage their own health we need to find ways to motivate and empower them to change – e.g. their diet, stress levels, physical activity or weight. Telling people to change may not be the best way to help them. Health Coaching and Shared Decision making may help you get better results.
In this lecture I give some tips on how to get better clinical outcomes via behavior change techniques.
Close

Toru Kikuchi

Saitama Medical University / Japan

Session Update on Evaluation and Management of Pediatric Hypertension
Lecture Title Diagnostic Criteria of Pediatric Hypertension in Japan: BP Reference Values, BP Classification
Lecture
Introduction
Accurate blood pressure measurement is essential for the diagnosis of hypertension. Even in children, right brachial blood pressure should be measured in a sitting position. The selection of an appropriate size cuff is also important. The cuff should be selected according to the size of the child’s upper arm rather than their age, and one with an inflatable bladder width exceeding 40% of the arm circumference and a length sufficient to cover 80% or more of the arm circumference should be used. Blood pressure should be consecutively measured ≥3 times, and the mean of two stable measurements should be adopted. If the blood pressure values measured at ≥3 different opportunities are above criteria, childhood hypertension could be diagnosed. In the Japanese Society of Hypertension 2019 Guidelines for the Management of Hypertension, criteria were established based on the data obtained on blood pressure screening using an automatic blood pressure meter by oscillometric methods. Diagnostic criteria: 6 to 8 years of age, ≥130/80 mmHg; and 9 to 11 years of age, ≥135/80 mmHg; and 12 to 14 years of age boys, ≥140/85 mmHg; and 12 to 14 years of age girls, ≥135/80 mmHg; and 15 to 17 years of age, ≥140/85 mmHg.
Session Update on Evaluation and Management of Pediatric Hypertension
Lecture Title Evaluation and Management of Pediatric Hypertension in Japan
Lecture
Introduction
secondary hypertension. Problems with essential hypertension in children and adolescents include target organ damage and tracking into adult essential hypertension. Childhood essential hypertension is related to obesity in many cases. Lifestyle modifications, such as diet, exercise, salt reduction, should be primarily performed. Drug therapy is indicated for children with hypertension meeting the following criteria: persistent hypertension despite non-drug therapy involving lifestyle modifications, symptomatic hypertension, secondary hypertension requiring drug therapy, the concomitant development of target organ damage, the presence of CKD or diabetes mellitus. For drug therapy, such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and Ca channel blockers are recommended.
Close

Yasuharu Tabara

Kyoto University Graduate School of Medicine / Japan

Session Optimizing Hypertension Management in the Elderly
Lecture Title Sleep Blood Pressure Management, Findings from the Nagahama Study
Lecture
Introduction
High sleep blood pressure is known to be a risk factor for cardiovascular outcomes independently of awaking blood pressure. However, factors influencing on sleep blood pressure has not been fully understood. The Nagahama study is a general population-based cohort study consists of 11,325 Japanese community-residents with multi-day measured sleep blood pressure. In this lecture, we introduce recent findings from the Nagahama study regarding sleep blood pressure measurements, variability, and factors influencing on sleep blood pressure to help better management of 24-h blood pressure.
Close

Yook Chin Chia

Sunway University / Malaysia

Session Joint Symposium of KSH/Malaysian Hypertension Society
[How to Manage Prehypertension Epidemics and Risk Factor Clustering]
Lecture Title Lifestyle Modification in Prehypertension
Lecture
Introduction
The word prehypertension was first introduced in May 2003 with the launch of the JNC-7. Prehypertension is defined as values of blood pressure (BP) readings between systolic 120–139 and/or diastolic 80–89 mmHg In the latest American hypertension guidelines of 2017, prehypertension has now been accepted as a diagnosis of Stage 1 hypertension. Part of the reasons for lowering the BP threshold from a systolic BP of ≥140 mmHg to ≥130 mmHg to define clinical hypertension was that cardiovascular disease (CVD) risk is actually a continuum across blood pressure. Furthermore it was being recognised that blood pressure readings between what is deemed optimal (ie ≤120/80 mmHg) and what is defined as clinical hypertension ( (BP ≥140/90 mmHg) is already associated with increased CVD risk and actual CVD events.
The prevalence of prehypertension is high and the progression to hypertension is also high. Prehypertension is also commonly associated with other CVD risk factors namely dyslipidaemia, dysgylcaemia and overweight/obesity. Eighty-five percent of prehypertensives have one other or more CVD risk factor compared to normotensives The aim of managing prehypertension is to lower the BP, prevent progression to hypertension and to prevent BP related CVD deaths. Lifestyle changes can reduce BP and this by itself can lower CVD risk. Currently there are no good outcome trials regarding the treatment of prehypertension with anti-hypertensive agents. Until more evidence about other modalities of treatment become available life-style modifications is a sensible and cost-effective way to manage prehypertension.
Close
TOP